Tag: porcine vaccine market size

Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.

Porcine Vaccine Market Size And Revenue Outlook Through 2030

The porcine vaccine market has experienced robust expansion in recent times. Forecasts indicate it is projected to increase from $2.05 billion in 2025 to $2.25 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.4%. Historically, this expansion has been driven by factors such as occurrences of swine disease outbreaks, an increase in pork consumption, advancements in traditional vaccine development, heightened veterinary awareness, and the enlargement of infrastructure for hog farming.

The porcine vaccine market is projected to experience substantial expansion over the coming years. This market is anticipated to reach $3.22 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.4%. This projected growth is driven by several factors, including the proliferation of recombinant and DNA vaccines, the uptake of precision veterinary medicine, a heightened emphasis on herd immunity schemes, innovations in vaccine delivery mechanisms, and increasing governmental efforts to promote livestock well-being. Key trends expected during this period involve the embrace of multi-strain vaccines for pigs, a growing emphasis on preventing diseases in swine populations, increased funding for swine immunization initiatives, the incorporation of veterinary consultation services into farm operations, and the enhancement of cold chain logistics for vaccine dissemination.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=9111&type=smp&name=Porcine%20Vaccine%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Porcine Vaccine Market Growth Backed By Core Demand Fundamentals

The expanding consumption of pork is projected to fuel the growth of the porcine vaccine market. This intake of pork, representing the quantity of pork meat consumed by people or groups within a defined period, has seen an increase correlating with the rising global population and greater demand for protein. The porcine vaccine market contributes to this heightened pork consumption by offering solutions that prevent diseases in pigs, thereby improving herd health and ensuring a steady supply of safe, high-quality pork products. An illustration of this trend is found in France, where, as reported in July 2024 by the INAPORC (Interprofession Nationale Porcine), a France-based national pork association, pork continued to be the most consumed meat in 2023, averaging around 30.6 kg per person per year. Thus, the increasing consumption of pork stands as a significant driver for the porcine vaccine market’s development.

Porcine Vaccine Market Segmentation And Category Overview

The porcine vaccine market covered in this report is segmented –

1) By Technology: Inactivated Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, Recombinant Vaccines, Conjugate Vaccines, DNA Vaccines

2) By Disease Indication: Diarrhea, Swine Influenza, Arthritis, Bordetella Rhinitis, Porcine Reproductive and Respiratory Virus (PRRSV), Porcine Circovirus Associated Disease (PCVAD), Other Disease Indications

3) By End User: Veterinary Hospitals, Hog Or Pig Production Farm

Subsegments:

1) By Inactivated Vaccines: Whole Virus Inactivated Vaccines, Subunit Inactivated Vaccines

2) By Live Attenuated Vaccines: Live Modified Vaccines, Live Virulent Vaccines

3) By Toxoid Vaccines: Inactivated Toxins

4) By Recombinant Vaccines: Recombinant Vector Vaccines, Subunit Recombinant Vaccines

5) By Conjugate Vaccines: Polysaccharide Conjugate Vaccines

6) By DNA Vaccines: Plasmid DNA Vaccines

Porcine Vaccine Market Growth Trends Reshaping The Competitive Landscape

Leading companies within the porcine vaccine market are embracing strategic alliances to bolster their research and development capabilities and reinforce their competitive standing in the rapidly evolving animal health industry. Such collaborations typically harness partners’ specific strengths, aiming to refine vaccine development and introduce novel approaches that can substantially benefit swine health. For example, in May 2024, The Pirbright Institute, a UK-based research organization, partnered with The Vaccine Group (TVG), a UK-based company, to develop a vaccine for African swine fever (ASF). This specific joint effort draws upon TVG’s proficiency in vaccine technology and Pirbright’s expertise in ASF research. The goal of this particular alliance is to improve the process of vaccine creation and devise innovative solutions capable of significantly advancing swine health. This research endeavors to formulate vaccines for preventing African swine fever (ASF) by utilizing bovine herpesvirus 4 (BoHV-4) as a base. This methodology capitalizes on the most recent discoveries in ASF vaccine investigation and pig immunology to craft more efficient vaccines. The initiative receives funding from the U.K.’s Department for Environment, Food and Rural Affairs (Defra) and the Biotechnology and Biological Sciences Research Council (BBSRC).

Porcine Vaccine Market Key Players Shaping Industry Direction

Major companies operating in the porcine vaccine market are Sanofi Pasteur Inc., Boehringer Ingelheim International GmbH, Zoetis Inc., Merck Animal Health, Elanco Animal Health Incorporated, Ceva Santé Animale, Huvepharma Inc., Phibro Animal Health Corporation, Vetoquinol SA, Intervet Inc., HIPRA S.A., IDT Biologika GmbH, Biogénesis Bagó, Aptimmune Biologics Inc., Virbac S.A., Vaxxinova International BV, Bioveta a.s., Indian Immunologicals Limited, KM Biologics, Addison Biological Laboratory, Colorado Serum Company, CAHIC China Animal Husbandry Industry Co, Tecon, Hile Bio, WINSUN

View The Full Porcine Vaccine Market Report:

https://thebusinessresearchcompany.com/report/porcine-vaccine-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Porcine Vaccine Market Regional Analysis: Which Region Leads By Revenue?

North America is the largest region in the porcine vaccine market in 2025. The regions covered in the porcine vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Market Value Trend Is Expected For The Porcine Vaccine Market From 2026 To 2030?

The porcine vaccine market size has shown robust expansion in recent years. It is anticipated to expand from $2.05 billion in 2025 to $2.25 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.4%. The factors contributing to this historic growth include outbreaks of swine diseases, increased pork consumption, the development of traditional vaccines, a rise in veterinary awareness, and the expansion of hog farming infrastructure.

The porcine vaccine market is projected to experience substantial expansion over the upcoming years. By 2030, its value is anticipated to reach $3.22 billion, exhibiting a compound annual growth rate (CAGR) of 9.4%. This anticipated growth during the forecast period is driven by several factors, including the increasing development of recombinant and DNA vaccines, the embrace of precision veterinary medicine, a heightened emphasis on herd immunity initiatives, progress in vaccine delivery technologies, and growing governmental efforts to improve livestock health. Key trends expected during this period involve the widespread use of multi-strain vaccines for pigs, a stronger emphasis on preventing diseases in swine populations, increased funding for swine immunization schemes, the incorporation of veterinary advisory services into farm operations, and the expansion of cold chain networks for vaccine distribution.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9111&type=smp

Which Strategic Drivers Are Supporting The Porcine Vaccine Market Development?

The increasing pork consumption is expected to propel the growth of the porcine vaccine market going forward. Pork consumption is the quantity of pork meat that people or groups eat in a specific amount of time. The consumption of pork has increased in tandem with the growing global population and the growing demand for protein. The porcine vaccine market supports increasing pork consumption, as vaccines help prevent diseases in pigs, improve herd health, and ensure a stable supply of safe and high-quality pork products. For instance, in July 2024, according to the INAPORC (Interprofession Nationale Porcine), a France-based national pork association, in 2023, pork was still the most consumed meat in France, with about 30.6 kg per person per year. Therefore, increasing pork consumption is driving the growth of the porcine vaccine market.

How Is The Porcine Vaccine Market Structured Across Different Market Segments?

The porcine vaccine market covered in this report is segmented –

1) By Technology: Inactivated Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, Recombinant Vaccines, Conjugate Vaccines, DNA Vaccines

2) By Disease Indication: Diarrhea, Swine Influenza, Arthritis, Bordetella Rhinitis, Porcine Reproductive and Respiratory Virus (PRRSV), Porcine Circovirus Associated Disease (PCVAD), Other Disease Indications

3) By End User: Veterinary Hospitals, Hog Or Pig Production Farm

Subsegments:

1) By Inactivated Vaccines: Whole Virus Inactivated Vaccines, Subunit Inactivated Vaccines

2) By Live Attenuated Vaccines: Live Modified Vaccines, Live Virulent Vaccines

3) By Toxoid Vaccines: Inactivated Toxins

4) By Recombinant Vaccines: Recombinant Vector Vaccines, Subunit Recombinant Vaccines

5) By Conjugate Vaccines: Polysaccharide Conjugate Vaccines

6) By DNA Vaccines: Plasmid DNA Vaccines

What Trends Are Driving Changes In The Porcine Vaccine Market?

Major companies operating in the porcine vaccine market are adapting strategic partnerships to enhance their research and development capabilities and strengthen their competitive position in the rapidly evolving animal health industry. The collaboration makes use of TVG’s experience in vaccine technology and Pirbright’s expertise in African swine fever (ASF) research. The goal of this partnership is to improve the vaccine development process and develop novel approaches that have the potential to greatly improve swine health. For instance, in May 2024, The Pirbright Institute, a UK-based research institute, partnered with The Vaccine Group (TVG), a UK-based company, to develop a vaccine for African swine fever (ASF), The research aims to develop vaccines to prevent African swine fever (ASF) by using bovine herpesvirus 4 (BoHV-4) as a foundation. This method takes advantage of the latest breakthroughs in ASF vaccine research and pig immunology to design more efficient vaccines. The initiative is funded by the U.K.’s Department for Environment, Food and Rural Affairs (Defra) and the Biotechnology and Biological Sciences Research Council (BBSRC).

Which Companies Are Engaged In The Porcine Vaccine Market Environment?

North America is the largest region in the porcine vaccine market in 2025. The regions covered in the porcine vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access The Complete Porcine Vaccine Market Report:

https://www.thebusinessresearchcompany.com/report/porcine-vaccine-global-market-report

Which Region Stands As The Largest Contributor To The Porcine Vaccine Market?

North America is the largest region in the porcine vaccine market in 2025. The regions covered in the porcine vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access a Customized Porcine Vaccine Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=9111&type=smp

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Market Value Trend Is Expected For The Porcine Vaccine Market From 2026 To 2030?

The porcine vaccine market size has shown robust expansion in recent years. It is anticipated to expand from $2.05 billion in 2025 to $2.25 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.4%. The factors contributing to this historic growth include outbreaks of swine diseases, increased pork consumption, the development of traditional vaccines, a rise in veterinary awareness, and the expansion of hog farming infrastructure.

The porcine vaccine market is projected to experience substantial expansion over the upcoming years. By 2030, its value is anticipated to reach $3.22 billion, exhibiting a compound annual growth rate (CAGR) of 9.4%. This anticipated growth during the forecast period is driven by several factors, including the increasing development of recombinant and DNA vaccines, the embrace of precision veterinary medicine, a heightened emphasis on herd immunity initiatives, progress in vaccine delivery technologies, and growing governmental efforts to improve livestock health. Key trends expected during this period involve the widespread use of multi-strain vaccines for pigs, a stronger emphasis on preventing diseases in swine populations, increased funding for swine immunization schemes, the incorporation of veterinary advisory services into farm operations, and the expansion of cold chain networks for vaccine distribution.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9111&type=smp

Which Strategic Drivers Are Supporting The Porcine Vaccine Market Development?

The increasing pork consumption is expected to propel the growth of the porcine vaccine market going forward. Pork consumption is the quantity of pork meat that people or groups eat in a specific amount of time. The consumption of pork has increased in tandem with the growing global population and the growing demand for protein. The porcine vaccine market supports increasing pork consumption, as vaccines help prevent diseases in pigs, improve herd health, and ensure a stable supply of safe and high-quality pork products. For instance, in July 2024, according to the INAPORC (Interprofession Nationale Porcine), a France-based national pork association, in 2023, pork was still the most consumed meat in France, with about 30.6 kg per person per year. Therefore, increasing pork consumption is driving the growth of the porcine vaccine market.

How Is The Porcine Vaccine Market Structured Across Different Market Segments?

The porcine vaccine market covered in this report is segmented –

1) By Technology: Inactivated Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, Recombinant Vaccines, Conjugate Vaccines, DNA Vaccines

2) By Disease Indication: Diarrhea, Swine Influenza, Arthritis, Bordetella Rhinitis, Porcine Reproductive and Respiratory Virus (PRRSV), Porcine Circovirus Associated Disease (PCVAD), Other Disease Indications

3) By End User: Veterinary Hospitals, Hog Or Pig Production Farm

Subsegments:

1) By Inactivated Vaccines: Whole Virus Inactivated Vaccines, Subunit Inactivated Vaccines

2) By Live Attenuated Vaccines: Live Modified Vaccines, Live Virulent Vaccines

3) By Toxoid Vaccines: Inactivated Toxins

4) By Recombinant Vaccines: Recombinant Vector Vaccines, Subunit Recombinant Vaccines

5) By Conjugate Vaccines: Polysaccharide Conjugate Vaccines

6) By DNA Vaccines: Plasmid DNA Vaccines

What Trends Are Driving Changes In The Porcine Vaccine Market?

Major companies operating in the porcine vaccine market are adapting strategic partnerships to enhance their research and development capabilities and strengthen their competitive position in the rapidly evolving animal health industry. The collaboration makes use of TVG’s experience in vaccine technology and Pirbright’s expertise in African swine fever (ASF) research. The goal of this partnership is to improve the vaccine development process and develop novel approaches that have the potential to greatly improve swine health. For instance, in May 2024, The Pirbright Institute, a UK-based research institute, partnered with The Vaccine Group (TVG), a UK-based company, to develop a vaccine for African swine fever (ASF), The research aims to develop vaccines to prevent African swine fever (ASF) by using bovine herpesvirus 4 (BoHV-4) as a foundation. This method takes advantage of the latest breakthroughs in ASF vaccine research and pig immunology to design more efficient vaccines. The initiative is funded by the U.K.’s Department for Environment, Food and Rural Affairs (Defra) and the Biotechnology and Biological Sciences Research Council (BBSRC).

Which Companies Are Engaged In The Porcine Vaccine Market Environment?

North America is the largest region in the porcine vaccine market in 2025. The regions covered in the porcine vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access The Complete Porcine Vaccine Market Report:

https://www.thebusinessresearchcompany.com/report/porcine-vaccine-global-market-report

Which Region Stands As The Largest Contributor To The Porcine Vaccine Market?

North America is the largest region in the porcine vaccine market in 2025. The regions covered in the porcine vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access a Customized Porcine Vaccine Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=9111&type=smp

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Increase Is Anticipated For The Anti-Inflammatory Biologics Market Over The 2026–2030 Period?

The porcine vaccine market has experienced substantial growth in recent years. Its valuation is expected to climb from $2.05 billion in 2025 to $2.25 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 9.4%. The expansion observed historically is due to factors such as outbreaks of swine diseases, increasing pork consumption, the development of traditional vaccines, greater veterinary awareness, and the growth of hog farming infrastructure.

The porcine vaccine market is anticipated to show significant expansion in the coming years, with projections indicating it will achieve a size of $3.22 billion in 2030, advancing at a compound annual growth rate (CAGR) of 9.4%. This growth over the forecast period is propelled by factors such as the development of recombinant and DNA vaccines, the adoption of precision veterinary medicine, an intensified focus on herd immunity programs, technological progress in vaccine delivery systems, and increasing government support for livestock health. Noteworthy trends during this time include the integration of multi-strain vaccines for pigs, a stronger emphasis on disease prevention within swine herds, increased financial backing for swine immunization initiatives, the incorporation of veterinary advisory services with farms, and the expansion of the cold chain infrastructure essential for vaccine distribution.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9111&type=smp

Which Major Factors Are Driving The Expansion Of The Anti-Inflammatory Biologics Market?

The escalating consumption of pork is anticipated to drive the expansion of the porcine vaccine market in the upcoming period. Pork consumption is defined as the amount of pork meat eaten by individuals or groups over a specific timeframe. The intake of pork has grown in parallel with the increasing global population and the rising demand for protein. The porcine vaccine market contributes to this heightened pork consumption by preventing diseases in pigs, improving the health of herds, and securing a steady provision of safe and high-quality pork products. As an illustration, in July 2024, information from INAPORC (Interprofession Nationale Porcine), a national pork association located in France, revealed that in 2023, pork continued to be the most consumed meat in France, at about 30.6 kg per person per year. Thus, the increasing consumption of pork is a key factor propelling the growth of the porcine vaccine market.

How Is The Anti-Inflammatory Biologics Market Segmented Across Key Categories?

The porcine vaccine market covered in this report is segmented –

1) By Technology: Inactivated Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, Recombinant Vaccines, Conjugate Vaccines, DNA Vaccines

2) By Disease Indication: Diarrhea, Swine Influenza, Arthritis, Bordetella Rhinitis, Porcine Reproductive and Respiratory Virus (PRRSV), Porcine Circovirus Associated Disease (PCVAD), Other Disease Indications

3) By End User: Veterinary Hospitals, Hog Or Pig Production Farm

Subsegments:

1) By Inactivated Vaccines: Whole Virus Inactivated Vaccines, Subunit Inactivated Vaccines

2) By Live Attenuated Vaccines: Live Modified Vaccines, Live Virulent Vaccines

3) By Toxoid Vaccines: Inactivated Toxins

4) By Recombinant Vaccines: Recombinant Vector Vaccines, Subunit Recombinant Vaccines

5) By Conjugate Vaccines: Polysaccharide Conjugate Vaccines

6) By DNA Vaccines: Plasmid DNA Vaccines

Which Upcoming Trends Are Expected To Influence The Porcine Vaccine Market?

Leading companies in the porcine vaccine market are forming strategic alliances to boost their research and development efforts and reinforce their competitive standing in the rapidly changing animal health industry. This collaborative approach leverages TVG’s expertise in vaccine technology and Pirbright’s specialized knowledge in African swine fever (ASF) research. The primary aim of such partnerships is to refine the vaccine development process and introduce novel methods that promise significant improvements in swine health. As an illustration, in May 2024, The Pirbright Institute, a research organization situated in the UK, joined forces with The Vaccine Group (TVG), a UK-based firm, to create an African swine fever (ASF) vaccine. This research endeavors to formulate vaccines to prevent African swine fever (ASF) using bovine herpesvirus 4 (BoHV-4) as a base. This methodology capitalizes on the latest advancements in ASF vaccine research and pig immunology to engineer more effective vaccines. The initiative receives funding from the U.K.’s Department for Environment, Food and Rural Affairs (Defra) and the Biotechnology and Biological Sciences Research Council (BBSRC).

Who Are The Dominant Players Shaping The Anti-Inflammatory Biologics Market Landscape?

Major companies operating in the porcine vaccine market are Sanofi Pasteur Inc., Boehringer Ingelheim International GmbH, Zoetis Inc., Merck Animal Health, Elanco Animal Health Incorporated, Ceva Santé Animale, Huvepharma Inc., Phibro Animal Health Corporation, Vetoquinol SA, Intervet Inc., HIPRA S.A., IDT Biologika GmbH, Biogénesis Bagó, Aptimmune Biologics Inc., Virbac S.A., Vaxxinova International BV, Bioveta a.s., Indian Immunologicals Limited, KM Biologics, Addison Biological Laboratory, Colorado Serum Company, CAHIC China Animal Husbandry Industry Co, Tecon, Hile Bio, WINSUN

Read the full porcine vaccine market report here:

https://www.thebusinessresearchcompany.com/report/porcine-vaccine-global-market-report

Which Region Currently Holds The Largest Share Of The Anti-Inflammatory Biologics Market?

North America is the largest region in the porcine vaccine market in 2025. The regions covered in the porcine vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Anti-Inflammatory Biologics Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=9111&type=smp

Browse Through More Reports Similar to the Global Porcine Vaccine Market 2026, By The Business Research Company

Porcine Epidemic Diarrhea Vaccines Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/porcine-epidemic-diarrhea-vaccines-global-market-report

Swine Vaccines Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/swine-vaccines-global-market-report

Veterinary Vaccines Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/veterinary-vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the digital rights management software market from 2026–2035 with trusted insights from The Business Research Company

What upper market value could the Porcine Vaccine Market reach by 2030 starting from 2026 levels?

The porcine vaccine market has seen robust growth in recent years. It is anticipated to increase from $2.05 billion in 2025 to $2.25 billion in 2026, registering a compound annual growth rate (CAGR) of 9.4%. Historically, this market expansion has been driven by outbreaks of swine diseases, rising pork consumption, the development of traditional vaccines, increasing veterinary awareness, and the expansion of hog farming infrastructure.

The porcine vaccine market is projected for significant expansion over the coming years, reaching a valuation of $3.22 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.4%. This anticipated growth throughout the forecast period stems from factors such as the proliferation of recombinant and DNA vaccines, the embrace of precision veterinary medicine, a heightened emphasis on herd immunity initiatives, continuous technological improvements in vaccine delivery methods, and escalating government efforts for animal health. Key developments anticipated during this period encompass the use of multi-strain vaccines for pigs, a stronger commitment to disease prevention within swine herds, increased financial commitments to swine immunization programs, the incorporation of veterinary advisory services into farm operations, and the broadening of cold chain infrastructure for vaccine dissemination.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9111&type=smp

Which Drivers Are Influencing Long-Term Growth In The Porcine Vaccine Market?

Growing pork consumption is projected to stimulate the expansion of the porcine vaccine market. Pork consumption denotes the quantity of pork meat consumed by individuals or groups within a specified timeframe. This consumption has increased in line with the growing global population and the rising demand for protein. The porcine vaccine market supports higher pork consumption by helping to prevent diseases in pigs, improve herd health, and ensure a stable supply of safe and high-quality pork products. For instance, in July 2024, according to INAPORC (Interprofession Nationale Porcine), a France-based national pork association, pork remained the most consumed meat in France in 2023, with approximately 30.6 kg per person per year. Thus, the escalating consumption of pork is driving the growth of the porcine vaccine market.

How Is The Porcine Vaccine Market Divided Into Segments?

The porcine vaccine market covered in this report is segmented –

1) By Technology: Inactivated Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, Recombinant Vaccines, Conjugate Vaccines, DNA Vaccines

2) By Disease Indication: Diarrhea, Swine Influenza, Arthritis, Bordetella Rhinitis, Porcine Reproductive and Respiratory Virus (PRRSV), Porcine Circovirus Associated Disease (PCVAD), Other Disease Indications

3) By End User: Veterinary Hospitals, Hog Or Pig Production Farm

Subsegments:

1) By Inactivated Vaccines: Whole Virus Inactivated Vaccines, Subunit Inactivated Vaccines

2) By Live Attenuated Vaccines: Live Modified Vaccines, Live Virulent Vaccines

3) By Toxoid Vaccines: Inactivated Toxins

4) By Recombinant Vaccines: Recombinant Vector Vaccines, Subunit Recombinant Vaccines

5) By Conjugate Vaccines: Polysaccharide Conjugate Vaccines

6) By DNA Vaccines: Plasmid DNA Vaccines

What Trends Are Driving The Growth Trajectory Of The Porcine Vaccine Market?

Key companies operating within the porcine vaccine sector are establishing strategic alliances to advance their research and development proficiencies and reinforce their competitive standing in the dynamic animal health industry. These collaborations leverage The Vaccine Group’s expertise in vaccine technology and The Pirbright Institute’s specialized knowledge in African swine fever (ASF) research. The aim of this partnership is to optimize the vaccine development process and devise innovative approaches that could significantly improve swine health. For example, in May 2024, The Pirbright Institute, a UK-based research institute, collaborated with The Vaccine Group (TVG), a UK-based company, to create a vaccine for African swine fever (ASF). The research intends to produce vaccines to prevent African swine fever (ASF) by employing bovine herpesvirus 4 (BoHV-4) as its fundamental basis. This strategy incorporates the latest advancements in ASF vaccine investigation and pig immunology to engineer more effective vaccines. The initiative is supported financially by the U.K.’s Department for Environment, Food and Rural Affairs (Defra) and the Biotechnology and Biological Sciences Research Council (BBSRC).

Which Major Industry Participants Are Leading The Porcine Vaccine Market Growth?

Major companies operating in the porcine vaccine market are Sanofi Pasteur Inc., Boehringer Ingelheim International GmbH, Zoetis Inc., Merck Animal Health, Elanco Animal Health Incorporated, Ceva Santé Animale, Huvepharma Inc., Phibro Animal Health Corporation, Vetoquinol SA, Intervet Inc., HIPRA S.A., IDT Biologika GmbH, Biogénesis Bagó, Aptimmune Biologics Inc., Virbac S.A., Vaxxinova International BV, Bioveta a.s., Indian Immunologicals Limited, KM Biologics, Addison Biological Laboratory, Colorado Serum Company, CAHIC China Animal Husbandry Industry Co, Tecon, Hile Bio, WINSUN

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/porcine-vaccine-global-market-report

Which Region Is Expected To Experience The Fastest Growth In The Porcine Vaccine Market?

North America is the largest region in the porcine vaccine market in 2025. The regions covered in the porcine vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Porcine Vaccine Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=9111&type=smp

Browse Through More Reports Similar to the Global Porcine Vaccine Market 2026, By The Business Research Company

Porcine Epidemic Diarrhea Vaccines Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/porcine-epidemic-diarrhea-vaccines-global-market-report

Swine Vaccines Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/swine-vaccines-global-market-report

Veterinary Vaccines Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/veterinary-vaccines-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Uncover key drivers, emerging technologies, and competitive movements shaping the porcine vaccine market from 2025–2034 with trusted insights from The Business Research Company

How Is The Porcine Vaccine Market Size Expected To Expand Over 2029-2034?

The market for porcine vaccines has experienced significant expansion recently; a valuation of $1.89 billion recorded in 2024 is projected to increase to $2.05 billion by 2025, reflecting an annualized growth rate of 8.5 percent. This upward trajectory during the past period is attributable to several factors, specifically the prevalence of disease outbreaks alongside necessitated control strategies, a worldwide surge in demand for pork products, the scaling up of pig rearing operations, supportive governmental actions aimed at limiting disease spread, and the proliferation of educational and awareness campaigns.

Anticipation surrounds the swine vaccination sector, predicting substantial expansion in the forthcoming years, with projections indicating it will reach a valuation of $2.94 billion by 2029, reflecting a consistent compound annual growth rate of 9.4%. This upward trajectory through the forecasted period is fueled by several key factors, notably the worldwide increase in hog rearing operations, escalating difficulties posed by animal diseases, increasingly strict governmental oversight and adherence requirements, progress in vaccine creation technology, and efforts related to international commerce and minimizing disease propagation risks. Significant shifts anticipated during this time involve tailoring vaccines to address specific local or regional issues, incorporating biotechnological methods into the creation of vaccines, mounting apprehension regarding diseases transmissible from animals to humans, utilizing genetic methods in designing vaccinations, and increased financial commitment directed towards research and development activities.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9111&type=smp

Which Market Factors Are Fueling The Porcine Vaccine Industry Growth?

Propelled by the escalating incidence of ailments affecting swine, the market for porcine vaccines is set for expansion in the near future. Swine influenza, often termed swine flu, is a typical respiratory affliction in pigs, predominantly brought on by the influenza A virus, which tends to spark regular flu episodes among swine populations. Porcine vaccines function by being administered to pigs, stimulating an immune response where the animal’s defense mechanisms recognize the vaccine and generate an immunological reaction that remembers the disease-causing agent. Consequently, these inoculations ready the swine’s system to combat harmful pathogens, offering protection against illness through an anamnestic response upon subsequent exposure to the identical pathogen. To illustrate the potential severity, reports from a United Kingdom information source in September 2024 indicated that an outbreak of African swine fever (ASF) posed a grave threat to the UK’s substantial pig sector, valued at 8 billion pounds, along with annual pork and related product exports amounting to 600 million pounds. The financial fallout from such an event is projected to fall anywhere between 10 million and 100 million pounds. Thus, the proliferation of swine diseases acts as a significant impetus for the growth trajectory of the porcine vaccine market.

Which Categories Are Covered In The Porcine Vaccine Market Segmentation Analysis?

The porcine vaccine market covered in this report is segmented –

1) By Technology: Inactivated Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, Recombinant Vaccines, Conjugate Vaccines, DNA Vaccines

2) By Disease Indication: Diarrhea, Swine Influenza, Arthritis, Bordetella Rhinitis, Porcine Reproductive and Respiratory Virus (PRRSV), Porcine Circovirus Associated Disease (PCVAD), Other Disease Indications

3) By End User: Veterinary Hospitals, Hog or Pig Production Farm

Subsegments:

1) By Inactivated Vaccines: Whole Virus Inactivated Vaccines, Subunit Inactivated Vaccines

2) By Live Attenuated Vaccines: Live Modified Vaccines, Live Virulent Vaccines

3) By Toxoid Vaccines: Inactivated Toxins

4) By Recombinant Vaccines: Recombinant Vector Vaccines, Subunit Recombinant Vaccines

5) By Conjugate Vaccines: Polysaccharide Conjugate Vaccines

6) By DNA Vaccines: Plasmid DNA Vaccines

Which Market Trends Are Expected To Define The Future Of The Porcine Vaccine Market?

Leading entities within the swine vaccine sector are actively engaging in strategic alliances to bolster their capabilities in innovation and research while simultaneously fortifying their standing amidst the swift transformations characterizing the animal health sector. This cooperative venture leverages The Vaccine Group’s proficiency in vaccine creation alongside Pirbright’s distinguished knowledge in the field of African swine fever (ASF) investigation. The overarching objective of this union is the refinement of vaccine creation methodologies and the pioneering of fresh strategies expected to yield substantial improvements in porcine well-being. To illustrate, in May of 2024, the United Kingdom’s Pirbright Institute established a cooperative arrangement with the UK firm, The Vaccine Group (TVG), specifically focused on engineering a prophylactic against African swine fever (ASF); this investigation is predicated on utilizing bovine herpesvirus 4 (BoHV-4) as the backbone for creating preventative injections against ASF. This approach capitalizes on recent advancements in both ASF vaccine science and pig immunology to formulate vaccines with greater efficacy, an undertaking receiving financial backing from the UK’s Department for Environment, Food and Rural Affairs (Defra) and the Biotechnology and Biological Sciences Research Council (BBSRC).

Which Organizations Are At The Forefront Of The Porcine Vaccine Market?

Major companies operating in the porcine vaccine market include Sanofi Pasteur Inc., Boehringer Ingelheim International GmbH, Zoetis Inc., Arko Laboratories Limited, Merck Animal Health, Elanco Animal Health Incorporated, Ceva Santé Animale, Huvepharma Inc., Phibro Animal Health Corporation, Vetoquinol SA, Intervet Inc., HIPRA S.A., Ringpu Bio-Pharmacy Co Ltd., IDT Biologika GmbH, Bimeda Holdings PLC, Jinyu Bio-Technology Co Ltd., Biogénesis Bagó, Pharmaq AS, Veterquimica S.A., Kyoto Biken Laboratories Inc., Dopharma Research B.V., Agrovet Market Animal Health Ltd., Innovad SA, PBS Animal Health, Merial Animal Health, Aptimmune Biologics Inc., Syntex SA de CV, Zoovet S.A., Shenzhen Weierkang Xiang Animal Pharm Co Ltd., Wuhan Keqian Biology Co Ltd., Anicon Labor GmbH

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/porcine-vaccine-global-market-report

Which Geographic Areas Are Driving Strong Demand For The Porcine Vaccine Market?

North America is the largest region in the porcine vaccine market in 2024. The regions covered in the porcine vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=9111&type=smp

Browse Through More Reports Similar to the Global Porcine Vaccine Market 2025, By The Business Research Company

Veterinary Infectious Disease Diagnostics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/veterinary-infectious-disease-diagnostics-global-market-report

Animal Antibiotics And Antimicrobials Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/animal-antibiotics-and-antimicrobials-global-market-report

Veterinary Antibiotics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/veterinary-antibiotics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

#What Is The Projected Market Size Of The Porcine Vaccine Market By 2029?

The porcine vaccine market has shown robust growth in recent years. This market is forecasted to expand from $1.89 billion in 2024 to $2.05 billion in 2025, progressing at a compound annual growth rate (CAGR) of 8.5%. Historically, this expansion has been propelled by elements such as disease outbreaks and implemented control measures, a global rise in pork consumption, the intensification of pig farming, government initiatives for disease control, and awareness and education programs.

The porcine vaccine market is projected to experience substantial expansion in the coming years, anticipated to reach $2.94 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 9.4%. This projected growth during the forecast period is attributable to factors such as the worldwide growth of pig farming, increasing disease threats, strict regulations and adherence requirements, innovations in vaccine technology, and global efforts in trade and disease risk reduction. Key trends anticipated within this period encompass tailoring vaccines to address specific regional issues, incorporating biotechnology into vaccine creation, heightened worries regarding zoonotic illnesses, utilizing genomic methods in vaccine formulation, and increasing financial commitments to research and development.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9111&type=smp

Which Drivers Are Supporting Growth Of The Porcine Vaccine Market?

The growing prevalence of swine diseases is projected to drive the expansion of the porcine vaccine market in the future. Swine influenza, often referred to as swine flu, is a respiratory ailment in pigs primarily triggered by the type A influenza virus, leading to common outbreaks among them. Porcine vaccines are administered to pigs, prompting their immune systems to respond and recognize the pathogenic agent by eliciting an immunogenic reaction. Such vaccines prime the swine’s immune system to combat pathogens and avert illness through an anamnestic reaction upon subsequent exposure to the same pathogen. For example, reports from the Government of the United Kingdom, an information website, indicated in September 2024 that an African swine fever (ASF) outbreak could significantly impact the UK’s pig industry, valued at £8 billion, and its £600 million yearly exports of pork and related products. The financial repercussions of such an event are estimated to be between £10 million and £100 million. Consequently, the increasing incidence of swine diseases is stimulating demand in the porcine vaccine market.

What Are The Emerging Segments Gaining Attention In The Porcine Vaccine Market?

The porcine vaccine market covered in this report is segmented –

1) By Technology: Inactivated Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, Recombinant Vaccines, Conjugate Vaccines, DNA Vaccines

2) By Disease Indication: Diarrhea, Swine Influenza, Arthritis, Bordetella Rhinitis, Porcine Reproductive and Respiratory Virus (PRRSV), Porcine Circovirus Associated Disease (PCVAD), Other Disease Indications

3) By End User: Veterinary Hospitals, Hog or Pig Production Farm

Subsegments:

1) By Inactivated Vaccines: Whole Virus Inactivated Vaccines, Subunit Inactivated Vaccines

2) By Live Attenuated Vaccines: Live Modified Vaccines, Live Virulent Vaccines

3) By Toxoid Vaccines: Inactivated Toxins

4) By Recombinant Vaccines: Recombinant Vector Vaccines, Subunit Recombinant Vaccines

5) By Conjugate Vaccines: Polysaccharide Conjugate Vaccines

6) By DNA Vaccines: Plasmid DNA Vaccines

Which Trends Are Impacting The Porcine Vaccine Market?

Leading entities within the porcine vaccine market are embracing strategic collaborations to bolster their research and development capacities and reinforce their competitive standing in the dynamic animal health sector. This collaborative effort leverages TVG’s proficiency in vaccine technology and Pirbright’s specialized knowledge in African swine fever (ASF) investigations. The primary objective of this alliance is to optimize the vaccine development procedure and conceive innovative strategies that could significantly advance swine health. An example of this is the partnership formed in May 2024, where The Pirbright Institute, a UK-based research institute, joined forces with The Vaccine Group (TVG), a UK-based company, with the aim of creating a vaccine for African swine fever (ASF). This research endeavors to produce vaccines capable of preventing African swine fever (ASF), utilizing bovine herpesvirus 4 (BoHV-4) as its underlying platform. Such an approach capitalizes on recent advancements in ASF vaccine studies and pig immunology to engineer more effective vaccines. Funding for this initiative is provided by the U.K.’s Department for Environment, Food and Rural Affairs (Defra) and the Biotechnology and Biological Sciences Research Council (BBSRC).

Who Are The Core Companies Influencing The Porcine Vaccine Market Landscape?

Major companies operating in the porcine vaccine market include Sanofi Pasteur Inc., Boehringer Ingelheim International GmbH, Zoetis Inc., Arko Laboratories Limited, Merck Animal Health, Elanco Animal Health Incorporated, Ceva Santé Animale, Huvepharma Inc., Phibro Animal Health Corporation, Vetoquinol SA, Intervet Inc., HIPRA S.A., Ringpu Bio-Pharmacy Co Ltd., IDT Biologika GmbH, Bimeda Holdings PLC, Jinyu Bio-Technology Co Ltd., Biogénesis Bagó, Pharmaq AS, Veterquimica S.A., Kyoto Biken Laboratories Inc., Dopharma Research B.V., Agrovet Market Animal Health Ltd., Innovad SA, PBS Animal Health, Merial Animal Health, Aptimmune Biologics Inc., Syntex SA de CV, Zoovet S.A., Shenzhen Weierkang Xiang Animal Pharm Co Ltd., Wuhan Keqian Biology Co Ltd., Anicon Labor GmbH

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/porcine-vaccine-global-market-report

What Are The Regional Market Dynamics Impacting The Porcine Vaccine Industry?

North America is the largest region in the porcine vaccine market in 2024. The regions covered in the porcine vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Porcine Vaccine Market Report:

https://www.thebusinessresearchcompany.com/customise?id=9111&type=smp

Browse Through More Reports Similar to the Global Porcine Vaccine Market 2025, By The Business Research Company

Veterinary Infectious Disease Diagnostics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/veterinary-infectious-disease-diagnostics-global-market-report

Animal Antibiotics And Antimicrobials Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/animal-antibiotics-and-antimicrobials-global-market-report

Veterinary Antibiotics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/veterinary-antibiotics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

#What Is The Projected Market Size Of The Porcine Vaccine Market By 2029?

The porcine vaccine market has shown robust growth in recent years. This market is forecasted to expand from $1.89 billion in 2024 to $2.05 billion in 2025, progressing at a compound annual growth rate (CAGR) of 8.5%. Historically, this expansion has been propelled by elements such as disease outbreaks and implemented control measures, a global rise in pork consumption, the intensification of pig farming, government initiatives for disease control, and awareness and education programs.

The porcine vaccine market is projected to experience substantial expansion in the coming years, anticipated to reach $2.94 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 9.4%. This projected growth during the forecast period is attributable to factors such as the worldwide growth of pig farming, increasing disease threats, strict regulations and adherence requirements, innovations in vaccine technology, and global efforts in trade and disease risk reduction. Key trends anticipated within this period encompass tailoring vaccines to address specific regional issues, incorporating biotechnology into vaccine creation, heightened worries regarding zoonotic illnesses, utilizing genomic methods in vaccine formulation, and increasing financial commitments to research and development.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9111&type=smp

Which Drivers Are Supporting Growth Of The Porcine Vaccine Market?

The growing prevalence of swine diseases is projected to drive the expansion of the porcine vaccine market in the future. Swine influenza, often referred to as swine flu, is a respiratory ailment in pigs primarily triggered by the type A influenza virus, leading to common outbreaks among them. Porcine vaccines are administered to pigs, prompting their immune systems to respond and recognize the pathogenic agent by eliciting an immunogenic reaction. Such vaccines prime the swine’s immune system to combat pathogens and avert illness through an anamnestic reaction upon subsequent exposure to the same pathogen. For example, reports from the Government of the United Kingdom, an information website, indicated in September 2024 that an African swine fever (ASF) outbreak could significantly impact the UK’s pig industry, valued at £8 billion, and its £600 million yearly exports of pork and related products. The financial repercussions of such an event are estimated to be between £10 million and £100 million. Consequently, the increasing incidence of swine diseases is stimulating demand in the porcine vaccine market.

What Are The Emerging Segments Gaining Attention In The Porcine Vaccine Market?

The porcine vaccine market covered in this report is segmented –

1) By Technology: Inactivated Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, Recombinant Vaccines, Conjugate Vaccines, DNA Vaccines

2) By Disease Indication: Diarrhea, Swine Influenza, Arthritis, Bordetella Rhinitis, Porcine Reproductive and Respiratory Virus (PRRSV), Porcine Circovirus Associated Disease (PCVAD), Other Disease Indications

3) By End User: Veterinary Hospitals, Hog or Pig Production Farm

Subsegments:

1) By Inactivated Vaccines: Whole Virus Inactivated Vaccines, Subunit Inactivated Vaccines

2) By Live Attenuated Vaccines: Live Modified Vaccines, Live Virulent Vaccines

3) By Toxoid Vaccines: Inactivated Toxins

4) By Recombinant Vaccines: Recombinant Vector Vaccines, Subunit Recombinant Vaccines

5) By Conjugate Vaccines: Polysaccharide Conjugate Vaccines

6) By DNA Vaccines: Plasmid DNA Vaccines

Which Trends Are Impacting The Porcine Vaccine Market?

Leading entities within the porcine vaccine market are embracing strategic collaborations to bolster their research and development capacities and reinforce their competitive standing in the dynamic animal health sector. This collaborative effort leverages TVG’s proficiency in vaccine technology and Pirbright’s specialized knowledge in African swine fever (ASF) investigations. The primary objective of this alliance is to optimize the vaccine development procedure and conceive innovative strategies that could significantly advance swine health. An example of this is the partnership formed in May 2024, where The Pirbright Institute, a UK-based research institute, joined forces with The Vaccine Group (TVG), a UK-based company, with the aim of creating a vaccine for African swine fever (ASF). This research endeavors to produce vaccines capable of preventing African swine fever (ASF), utilizing bovine herpesvirus 4 (BoHV-4) as its underlying platform. Such an approach capitalizes on recent advancements in ASF vaccine studies and pig immunology to engineer more effective vaccines. Funding for this initiative is provided by the U.K.’s Department for Environment, Food and Rural Affairs (Defra) and the Biotechnology and Biological Sciences Research Council (BBSRC).

Who Are The Core Companies Influencing The Porcine Vaccine Market Landscape?

Major companies operating in the porcine vaccine market include Sanofi Pasteur Inc., Boehringer Ingelheim International GmbH, Zoetis Inc., Arko Laboratories Limited, Merck Animal Health, Elanco Animal Health Incorporated, Ceva Santé Animale, Huvepharma Inc., Phibro Animal Health Corporation, Vetoquinol SA, Intervet Inc., HIPRA S.A., Ringpu Bio-Pharmacy Co Ltd., IDT Biologika GmbH, Bimeda Holdings PLC, Jinyu Bio-Technology Co Ltd., Biogénesis Bagó, Pharmaq AS, Veterquimica S.A., Kyoto Biken Laboratories Inc., Dopharma Research B.V., Agrovet Market Animal Health Ltd., Innovad SA, PBS Animal Health, Merial Animal Health, Aptimmune Biologics Inc., Syntex SA de CV, Zoovet S.A., Shenzhen Weierkang Xiang Animal Pharm Co Ltd., Wuhan Keqian Biology Co Ltd., Anicon Labor GmbH

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/porcine-vaccine-global-market-report

What Are The Regional Market Dynamics Impacting The Porcine Vaccine Industry?

North America is the largest region in the porcine vaccine market in 2024. The regions covered in the porcine vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Porcine Vaccine Market Report:

https://www.thebusinessresearchcompany.com/customise?id=9111&type=smp

Browse Through More Reports Similar to the Global Porcine Vaccine Market 2025, By The Business Research Company

Veterinary Infectious Disease Diagnostics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/veterinary-infectious-disease-diagnostics-global-market-report

Animal Antibiotics And Antimicrobials Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/animal-antibiotics-and-antimicrobials-global-market-report

Veterinary Antibiotics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/veterinary-antibiotics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Key Projections for the CAGR of the Porcine Vaccine Market Size From 2025 to 2034?

The market size for porcine vaccines has been expanding significantly in the last few years. Its progression from $1.89 billion in 2024 to $2.05 billion in 2025, with a compound annual growth rate (CAGR) of 8.5%, is quite impressive. The factors contributing to this development during the historical period include disease outbreaks and the actions taken to control them, a worldwide rise in pork intake, the fortification of pig farming, government schemes aimed at disease control, as well as initiatives to increase awareness and education.

The market for porcine vaccines is predicted to experience a hefty expansion in the upcoming years, inflating to $2.94 billion by 2029 with a compound annual growth rate (CAGR) of 9.4%. The surge during the projection period can be credited to the worldwide growth of pig farming, increasing disease threats, strict regulations and adherence, advances in vaccine research, international commerce, and disease risk reduction. Key trends during this period encompass vaccine customization for regional challenges, the integration of biotechnology with vaccine creation, increased alarm over zoonotic diseases, the use of genomic methods in vaccine design, and escalating investment in research and development.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9111&type=smp

What External and Internal Drivers Are Contributing to the Growth of thePorcine Vaccine Market?

The growth of the porcine vaccine market is set to be propelled by the escalating incidence of swine disease. A common respiratory condition affecting pigs, swine flu (swine influenza) is typically triggered by the type A influenza virus, which is known to prompt frequent outbreaks among pigs. By introducing porcine vaccines to pigs, their immune systems respond and remember the pathogenic agent by triggering an immunogenic reaction. These vaccinations equip the pigs’ immune systems to resist pathogens, thereby averting disease by invoking an anamnestic response upon the next encounter with that same pathogen. As an example, the UK Government cited an information website based in the UK in September 2024, warning that a potential African swine fever (ASF) outbreak could significantly harm the UK’s pig sector, valued at £8 billion, and its annual £600 million exports of pork and related products. They projected the likely financial repercussion of such an outbreak could be anywhere between £10 million-£100 million. Thus, the increasing prevalence of swine diseases is spurring the growth of the porcine vaccine market.

What Segment Types Define the Porcine Vaccine Market Structure?

The porcine vaccine market covered in this report is segmented –

1) By Technology: Inactivated Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, Recombinant Vaccines, Conjugate Vaccines, DNA Vaccines

2) By Disease Indication: Diarrhea, Swine Influenza, Arthritis, Bordetella Rhinitis, Porcine Reproductive and Respiratory Virus (PRRSV), Porcine Circovirus Associated Disease (PCVAD), Other Disease Indications

3) By End User: Veterinary Hospitals, Hog or Pig Production Farm

Subsegments:

1) By Inactivated Vaccines: Whole Virus Inactivated Vaccines, Subunit Inactivated Vaccines

2) By Live Attenuated Vaccines: Live Modified Vaccines, Live Virulent Vaccines

3) By Toxoid Vaccines: Inactivated Toxins

4) By Recombinant Vaccines: Recombinant Vector Vaccines, Subunit Recombinant Vaccines

5) By Conjugate Vaccines: Polysaccharide Conjugate Vaccines

6) By DNA Vaccines: Plasmid DNA Vaccines

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=9111&type=smp

Which Geographic Areas Hold the Strongest Growth Potential in the Porcine Vaccine Market?

North America is the largest region in the porcine vaccine market in 2024. The regions covered in the porcine vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Long-Term Trends Are Transforming the Competitive Landscape of the Porcine Vaccine Market?

Leading players in the porcine vaccine industry are adopting strategic collaborations to bolster their research and developmental competencies and fortify their competitive stance in the rapidly advancing animal health sector. This partnership leverages the capabilities of TVG in vaccine technology and the prowess of Pirbright in African swine fever (ASF) research. The primary motive of this collaborative exercise is to streamline the process of vaccine development and discover innovative methods with the potential to significantly enhance swine health. In the instance of May 2024, The Pirbright Institute and The Vaccine Group (TVG), both based in the UK, allied to engender a vaccine for African swine fever (ASF). The objective of this research is to create vaccines for the prevention of ASF by employing bovine herpesvirus 4 (BoHV-4) as a base. This technique exploits the most recent discoveries in ASF vaccine research and pig immunology to construct more effective vaccines. The UK’s Department for Environment, Food and Rural Affairs (Defra) and the Biotechnology and Biological Sciences Research Council (BBSRC) financially supports this endeavour.

View the full report here:

https://www.thebusinessresearchcompany.com/report/porcine-vaccine-global-market-report

What Is the Definition of the Porcine Vaccine Market?

Porcine vaccines are a medical and pharmaceutical treatment that improves the health of pigs by shielding them from different bacteria, viruses, and other infections. It is used to increase the efficacy of protecting pigs from harmful ailments while increasing the output of top-notch meat for human consumption.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9111

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Key Projections for the CAGR of the Porcine Vaccine Market Size From 2025 to 2034?

The market size for porcine vaccines has been expanding significantly in the last few years. Its progression from $1.89 billion in 2024 to $2.05 billion in 2025, with a compound annual growth rate (CAGR) of 8.5%, is quite impressive. The factors contributing to this development during the historical period include disease outbreaks and the actions taken to control them, a worldwide rise in pork intake, the fortification of pig farming, government schemes aimed at disease control, as well as initiatives to increase awareness and education.

The market for porcine vaccines is predicted to experience a hefty expansion in the upcoming years, inflating to $2.94 billion by 2029 with a compound annual growth rate (CAGR) of 9.4%. The surge during the projection period can be credited to the worldwide growth of pig farming, increasing disease threats, strict regulations and adherence, advances in vaccine research, international commerce, and disease risk reduction. Key trends during this period encompass vaccine customization for regional challenges, the integration of biotechnology with vaccine creation, increased alarm over zoonotic diseases, the use of genomic methods in vaccine design, and escalating investment in research and development.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9111&type=smp

What External and Internal Drivers Are Contributing to the Growth of thePorcine Vaccine Market?

The growth of the porcine vaccine market is set to be propelled by the escalating incidence of swine disease. A common respiratory condition affecting pigs, swine flu (swine influenza) is typically triggered by the type A influenza virus, which is known to prompt frequent outbreaks among pigs. By introducing porcine vaccines to pigs, their immune systems respond and remember the pathogenic agent by triggering an immunogenic reaction. These vaccinations equip the pigs’ immune systems to resist pathogens, thereby averting disease by invoking an anamnestic response upon the next encounter with that same pathogen. As an example, the UK Government cited an information website based in the UK in September 2024, warning that a potential African swine fever (ASF) outbreak could significantly harm the UK’s pig sector, valued at £8 billion, and its annual £600 million exports of pork and related products. They projected the likely financial repercussion of such an outbreak could be anywhere between £10 million-£100 million. Thus, the increasing prevalence of swine diseases is spurring the growth of the porcine vaccine market.

What Segment Types Define the Porcine Vaccine Market Structure?

The porcine vaccine market covered in this report is segmented –

1) By Technology: Inactivated Vaccines, Live Attenuated Vaccines, Toxoid Vaccines, Recombinant Vaccines, Conjugate Vaccines, DNA Vaccines

2) By Disease Indication: Diarrhea, Swine Influenza, Arthritis, Bordetella Rhinitis, Porcine Reproductive and Respiratory Virus (PRRSV), Porcine Circovirus Associated Disease (PCVAD), Other Disease Indications

3) By End User: Veterinary Hospitals, Hog or Pig Production Farm

Subsegments:

1) By Inactivated Vaccines: Whole Virus Inactivated Vaccines, Subunit Inactivated Vaccines

2) By Live Attenuated Vaccines: Live Modified Vaccines, Live Virulent Vaccines

3) By Toxoid Vaccines: Inactivated Toxins

4) By Recombinant Vaccines: Recombinant Vector Vaccines, Subunit Recombinant Vaccines

5) By Conjugate Vaccines: Polysaccharide Conjugate Vaccines

6) By DNA Vaccines: Plasmid DNA Vaccines

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=9111&type=smp

Which Geographic Areas Hold the Strongest Growth Potential in the Porcine Vaccine Market?

North America is the largest region in the porcine vaccine market in 2024. The regions covered in the porcine vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Long-Term Trends Are Transforming the Competitive Landscape of the Porcine Vaccine Market?

Leading players in the porcine vaccine industry are adopting strategic collaborations to bolster their research and developmental competencies and fortify their competitive stance in the rapidly advancing animal health sector. This partnership leverages the capabilities of TVG in vaccine technology and the prowess of Pirbright in African swine fever (ASF) research. The primary motive of this collaborative exercise is to streamline the process of vaccine development and discover innovative methods with the potential to significantly enhance swine health. In the instance of May 2024, The Pirbright Institute and The Vaccine Group (TVG), both based in the UK, allied to engender a vaccine for African swine fever (ASF). The objective of this research is to create vaccines for the prevention of ASF by employing bovine herpesvirus 4 (BoHV-4) as a base. This technique exploits the most recent discoveries in ASF vaccine research and pig immunology to construct more effective vaccines. The UK’s Department for Environment, Food and Rural Affairs (Defra) and the Biotechnology and Biological Sciences Research Council (BBSRC) financially supports this endeavour.

View the full report here:

https://www.thebusinessresearchcompany.com/report/porcine-vaccine-global-market-report

What Is the Definition of the Porcine Vaccine Market?

Porcine vaccines are a medical and pharmaceutical treatment that improves the health of pigs by shielding them from different bacteria, viruses, and other infections. It is used to increase the efficacy of protecting pigs from harmful ailments while increasing the output of top-notch meat for human consumption.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9111

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model